ABUS Arbutus Biopharma Corporation

NASDAQ
$4.85

Arbutus Biopharma Corporation (ABUS) is expected to report earnings on November 9, 2026, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of +5.7% since its last earnings release on August 12, 2026.

Arbutus Biopharma Reported Earnings
Wednesday, August 12, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 7:30 AM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.08

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.